Tresto-Med, Testosterone Mix, 100 mg/ml, 10 ml

Tresto-Med by Bioniche Pharma features Trestolone ($7\alpha$-methyl-19-nortestosterone / MENT), a high-potency synthetic androgen formulation developed for exceptional tissue-selective anabolic activity. Engineered by Bioniche Pharma to deliver rapid therapeutic onset, Bioniche Pharma Tresto-Med stimulates skeletal muscle protein synthesis, speeds lipolysis, and maintains positive nitrogen conservation without converting into dihydrotestosterone (DHT).

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

The structural modification of Trestolone includes a $7\alpha$-methyl addition that prevents interaction with $5\alpha$-reductase, avoiding $5\alpha$-reduction into DHT-based metabolites. Bioniche Pharma Tresto-Med displays minimal affinity for mineralocorticoid or progesterone receptors and does not bind substantially to Sex Hormone-Binding Globulin (SHBG), ensuring that a high concentration of active compound remains free and bioavailable. Although non-susceptible to $5\alpha$-reduction, Tresto-Med by Bioniche Pharma undergoes aromatization to support essential estrogen-dependent systemic pathways.

Pharmacological evaluation demonstrates an anabolic-to-androgenic ratio of approximately $2300:650$ compared to standard testosterone, with preclinical studies showing $10\text{--}23\times$ higher anabolic potency than endogenous testosterone and a $12\times$ greater suppressive influence on the Hypothalamic-Pituitary-Testicular Axis (HPTA).

INDICATIONS & CLINICAL USE

• Investigational hormonal protocols for male contraception through rapid, reversible inhibition of spermatogenesis using Bioniche Pharma Tresto-Med.
• Therapeutic intervention for severe muscle degradation, including cachexia and age-related sarcopenia.
• Androgen replacement therapy for primary male hypogonadism and testosterone deficiency states.
• Supportive management for severe bone mineral loss and osteoporosis under clinical supervision.
• Exploratory protocols in benign prostatic hyperplasia, prostate cancer management, and androgenic alopecia regimens using Tresto-Med by Bioniche Pharma.

CONTRAINDICATIONS

• Pediatric patients, adolescents, and individuals under 18 years of age due to severe risks of precocious puberty and premature epiphyseal closure.
• Male patients with diagnosed or suspected prostate carcinoma or male breast cancer.
• Women who are pregnant or nursing due to extreme risks of fetal virilization, developmental abnormalities, and endocrine toxicity.
• Patients with documented hypersensitivity to Trestolone Acetate, vehicle oils, or compounding ingredients in Bioniche Pharma formulations.

ADVERSE REACTIONS & SPECIAL PRECAUTIONS

• Severe HPTA Suppression: Owing to its significant biological activity, Bioniche Pharma Tresto-Med causes rapid and profound suppression of gonadotropin release (LH and FSH), leading to temporary cessation of endogenous testosterone synthesis and spermatogenesis.
• Estrogenic Side Effects: Because Trestolone undergoes aromatization, surveillance for estrogen-linked events (including gynecomastia and fluid accumulation) is recommended during Bioniche Pharma Tresto-Med therapy.
• Metabolic & Systemic: Pronounced increase in appetite and alterations in baseline metabolic rate. Notably, Trestolone shows no significant polycythemic elevation in hemoglobin or hematocrit levels.

DOSAGE & ADMINISTRATION

Given the exceptional potency and fast absorption kinetics of Bioniche Pharma Tresto-Med, dosing schedules must be carefully calculated, started at conservative levels, and managed under qualified medical direction.

STORAGE & HANDLING

Keep Bioniche Pharma Tresto-Med in a dry, cool environment protected from direct sunlight exposure and elevated temperatures. Do not refrigerate or freeze. Store securely out of the reach and sight of children.